The statistic that one man dies of prostate cancer every 45 minutes is shocking. But what does it mean for an individual man? We explain the facts behind the figure.
BLOG: Dr Ian Le Guillou looks back on the past 12 months of prostate cancer breakthroughs, picking out the ones that made the biggest splash and previewing what we can look forward to in 2019.
We're funding Dr Alison Tree, an oncologist at the Royal Marsden, to trial a new kind of radiotherapy that keeps hormone therapy working for longer in men with advanced disease. She tells us about the cutting-edge technology behind the potential new treatment and the big hopes she has for it.
BLOG: Our research comms officer, Ruby Kell, explains how a promising new test we're funding could help identify men whose radiotherapy is likely to fail, then target them with a commonly-used drug that will stop the treatment from being thwarted.
Hayley Yarnley knows how much our new precision medicine research programme could have helped her father, Bernie, who died from advanced prostate cancer last December. She describes how the births of her children kept him going during his treatment, and why he was convinced scientists would one day find a cure.
The latest results from the STAMPEDE trial have shown immediate radiotherapy with standard hormone therapy could increase the survival of thousands of men diagnosed with advanced prostate cancer that hasn't spread too widely. We're now calling for the treatment to be offered to these men as standard on the NHS.
As part of our Research Innovation Awards, we’re funding Professor Claire Lewis at the University of Sheffield to see if it's possible to train men’s own immune systems to fight back at prostate cancer and prevent it from returning. She explains the fascinating 'Trojan horse' science behind this new example of Immunotherapy research.
The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
A five-year early-stage study of high-intensity focused ultrasound resulted in tumour progression being halted in men with intermediate-risk, localised prostate cancer. But more evidence is needed to prove its benefits hold up against existing treatment options and for all men with the disease.
Preventing resistance to hormone therapy is a key goal for researchers trying to improve prostate cancer treatment. Now, research funded by us – thanks to your donations – has revealed that the immune system could have a part to play.